Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review.

Bibliographic Details
Title: Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review.
Authors: Menezes, Luis Felipe Santos, Sabiá Júnior, Elias Ferreira, Tibery, Diogo Vieira, Carneiro, Lilian dos Anjos, Schwartz, Elisabeth Ferroni
Source: Frontiers in Pharmacology; 8/18/2020, Vol. 11, pN.PAG-N.PAG, 32p
Subject Terms: BRUGADA syndrome, SODIUM channels, EPILEPSY, ION channels, MISSENSE mutation
Abstract: Epilepsy is a disease characterized by abnormal brain activity and a predisposition to generate epileptic seizures, leading to neurobiological, cognitive, psychological, social, and economic impacts for the patient. There are several known causes for epilepsy; one of them is the malfunction of ion channels, resulting from mutations. Voltage-gated sodium channels (NaV) play an essential role in the generation and propagation of action potential, and malfunction caused by mutations can induce irregular neuronal activity. That said, several genetic variations in NaV channels have been described and associated with epilepsy. These mutations can affect channel kinetics, modifying channel activation, inactivation, recovery from inactivation, and/or the current window. Among the NaV subtypes related to epilepsy, NaV1.1 is doubtless the most relevant, with more than 1500 mutations described. Truncation and missense mutations are the most observed alterations. In addition, several studies have already related mutated NaV channels with the electrophysiological functioning of the channel, aiming to correlate with the epilepsy phenotype. The present review provides an overview of studies on epilepsy-associated mutated human NaV1.1, NaV1.2, NaV1.3, NaV1.6, and NaV1.7. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:16639812
DOI:10.3389/fphar.2020.01276
Published in:Frontiers in Pharmacology
Language:English